| 초록 |
The use of monoclonal antibodies (mAbs), which specifically bind to target molecules with high affinity, is of interest for many pharmaceutical and industrial applications. As of January 2017, more than 52 mAbs have been clinically approved in worldwide for diverse indications, mainly cancers and autoimmune/inflammatory diseases. There are great needs for the development of innovative mAbs against new targets and next-generation mAbs with superior profiles to current mAbs. Next-generation antibody will show greater clinical efficacy, reduced side-effects, and more convenient administrations as well as target proteins previously inaccessible by conventional antibody. In this talk, I will discuss our effort to develop proprietary platform technology for next generation antibody therapeutics, including bispecific antibody, tumor tissue penetrating antibody, and cell-penetrating antibody for targeting of intracellular molecules. |
